NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Small Business SMB
H.R. 4, S. 18 and S. 72, bills which would repeal the expanded 1099 form filing requirements; H.R. 605 and S. 312, Patients Freedom to Choose Act of 2011, repeals provisions of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 that restrict payments from health savings accounts, medical savings accounts, and health flexible spending arrangements for medications to prescription drugs and insulin only; sent letter to House and Senate Members in support of allowing the Federal Reserve to finalize the rule which would limit the amount of interchange (or swipe) fees that banks could charge on debit card transactions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| JOHN M COSTER | — |
| ADNAN JALIL | — |
| DAVID SANDERS | — |
Pharmacy PHA
H.R. 979, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2011, legislation to reform the oversight authority for OPM for FEHBP drug benefit; H.R. 891 and S. 274, Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, Fairness in Medicare Bidding Act , this legislation would repeal the competitive bidding program in the Medicare Part B durable medical equipment prosthetics, orthotics and supplies (DMEPOS) program; worked with House and Senate Members on Congressional letter to CMS regarding the pending rule which was to be published on the new short cycle requirements for long-term care prescription dispensing; continue to work with Senate Committee on Aging on potential legislation addressing the role of nurses as agents in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study they are conducting on the 340B drug program which was mandated by Congress; FY12 National Defense Authorization Act, includes funding for for the TRICARE pharmacy program (bill not yet introduced); H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions relating to pedigree and track and trace-no bill introduced in the current Congress; H.R. 5234, the PBM Audit Reform ad Transparency Act of 2010 (111th Congress), no bill introduced in this Congress; H.R. 5235, Medicare Access to Diabetes Supplies Act (111th Congress), no bill introduced in this Congress; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national pharmacy benefit manager (PBM); submitted comments to House Energy and Commerce Committee for a hearing on the impact of health care reform on providers; submitted comments to House Committee on Oversight and Government Reform regarding the impact of certain regulations on small business pharmacies; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids From Dangerous Drugs Act of 2011.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| JOHN M COSTER | — |
| ADNAN JALIL | — |
| SUSAN JANECZKO | — |
| DAVID SANDERS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.